AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36483268 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety symptom cluster
Number of subjects: 596
Study 36483582 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies targeting the PD-1/PD-L1 signaling axis
Number of subjects: 123
Study 36483622 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor loading dose (LD)
Number of subjects: 0
Study 36483622 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel loading dose (LD)
Number of subjects: 0
Study 36483698 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversational hypnosis (CH)
Number of subjects: 167
Study 36483698 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (without CH)
Number of subjects: 167
Study 36484260 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac stromal cells secreting GDF3
Number of subjects: 0
Study 36484260 — intervention group
Group type: COMPARATOR
Intervention: Cardiac stromal cells
Number of subjects: 0
Study 36484484 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd155-RSV (low dose)
Number of subjects: 82
Study 36484484 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd155-RSV (medium dose)
Number of subjects: 82
Study 36484484 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd155-RSV (high dose)
Number of subjects: 82
Study 36484484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 36485022 — intervention group
Group type: EXPERIMENTAL
Intervention: SmokefreeSGM
Number of subjects: 80
Study 36485022 — intervention group
Group type: COMPARATOR
Intervention: SmokefreeTXT (control)
Number of subjects: 80
Study 36485070 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal/intravenous (IP/IV) chemotherapy in HTB subgroup
Number of subjects: 0
Study 36485070 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) chemotherapy in HTB subgroup
Number of subjects: 0
Study 36485070 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal/intravenous (IP/IV) chemotherapy in LTB subgroup
Number of subjects: 0
Study 36485070 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) chemotherapy in LTB subgroup
Number of subjects: 0
Study 36485104 — intervention group
Group type: EXPERIMENTAL
Intervention: Up-front autologous stem cell transplantation (ASCT)
Number of subjects: 0
Study 36485104 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemoimmunotherapy followed by ASCT
Number of subjects: 0
Study 36485104 — intervention group
Group type: COMPARATOR
Intervention: Maintenance rituximab alone
Number of subjects: 0
Study 36485104 — intervention group
Group type: COMPARATOR
Intervention: Chemoimmunotherapy induction and maintenance with and without ASCT
Number of subjects: 0
Study 36490302 — intervention group
Group type: EXPERIMENTAL
Intervention: Etranacogene dezaparvovec (2 × 10^13 gene copies per kg)
Number of subjects: 3
Study 36490302 — intervention group
Group type: EXPERIMENTAL
Intervention: Etranacogene dezaparvovec
Number of subjects: 3
Study 36493334 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy
Number of subjects: 0
Study 36493334 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36493463 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Maximum Likelihood Estimation (TMLE)
Number of subjects: 0
Study 36493463 — intervention group
Group type: COMPARATOR
Intervention: G-computation
Number of subjects: 0
Study 36493463 — intervention group
Group type: COMPARATOR
Intervention: Inverse Probability Weighting Estimators
Number of subjects: 0
Study 36493574 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus lenvatinib
Number of subjects: 0
Study 36493574 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 36493580 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 700
Study 36493603 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment using a tablet application for detecting herb and food-drug interactions (HFDIs).
Number of subjects: 143
Study 36494591 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 150 mg/day (3 days) followed by 300 mg/day (4 days)
Number of subjects: 51
Study 36494591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 36494591 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol
Number of subjects: 51
Study 36494591 — intervention group
Group type: COMPARATOR
Intervention: Solriamfetol and Placebo
Number of subjects: 51
Study 36494725 — intervention group
Group type: EXPERIMENTAL
Intervention: KTE-X19 (1 × 10^6 CAR T cells)
Number of subjects: 55
Study 36494725 — intervention group
Group type: COMPARATOR
Intervention: Matched historical controls (SCHOLAR-3)
Number of subjects: 55
Study 36494743 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-titre Group O whole blood (LTOWB)
Number of subjects: 52
Study 36494743 — intervention group
Group type: COMPARATOR
Intervention: Packed red blood cells (PRBC)
Number of subjects: 52
Study 36494743 — intervention group
Group type: COMPARATOR
Intervention: Freeze-dried plasma
Number of subjects: 52
Study 36494748 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Resilience Skills Training (ERST) tailored for diverse PSP
Number of subjects: 0
Study 36494748 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing evidence-based assessments (annual, monthly, daily)
Number of subjects: 0
Study 36494776 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal diagnostic assessments including behavioral scales, quantitative electroencephalography, transcranial magnetic stimulation with electroencephalography, structural and resting-state functional MRI, and physiological activity measurements.
Number of subjects: 0
Study 36494776 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessments of caregivers' well-being and treatment decision attitudes.
Number of subjects: 0
Study 36494840 — intervention group
Group type: EXPERIMENTAL
Intervention: Cook Like A Boss Online intervention
Number of subjects: 248
Study 36494874 — intervention group
Group type: EXPERIMENTAL
Intervention: Brainstem raphe hypoechogenicity (BRH) identified by transcranial sonography (TCS)
Number of subjects: 100
Study 36495395 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype B (subclinical macular edema with decreased vessel density < 2 SD of healthy controls)
Number of subjects: 122
Study 36495395 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype C (decreased vessel density ≥ 2 SD of healthy controls)
Number of subjects: 122
Study 36495795 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence music therapy (60-minute sessions, twice a week for 4 weeks)
Number of subjects: 0
Study 36495795 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 36495927 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based multi-cancer early detection (MCED) test
Number of subjects: 4077
Study 36496135 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadless pacemaker implantation following transvenous lead extraction (TLE)
Number of subjects: 1179
Study 36496135 — intervention group
Group type: COMPARATOR
Intervention: De novo leadless pacemaker implantation
Number of subjects: 1179
Study 36496135 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadless pacemaker implantation at a different right ventricular (RV) location than previous transvenous RV lead extraction
Number of subjects: 1179
Study 36496395 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal DNA detection in nasopharynx
Number of subjects: 677
Study 36496395 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal concentration (Ct value)
Number of subjects: 677
Study 36496395 — intervention group
Group type: COMPARATOR
Intervention: Presence of serotype 19F
Number of subjects: 677
Study 36496395 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotypes associated with radiological pneumonia
Number of subjects: 677
Study 36496395 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotypes included in PCV13 vaccine
Number of subjects: 677
Study 36496395 — intervention group
Group type: EXPERIMENTAL
Intervention: Infections with multiple serotypes
Number of subjects: 677
Study 36496395 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR-determined concentrations of pneumococci
Number of subjects: 677
Study 36496547 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 187
Study 36496547 — intervention group
Group type: COMPARATOR
Intervention: Other Tx
Number of subjects: 187
Study 36497620 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Vigorous Physical Activity (PA)
Number of subjects: 105
Study 36497620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF)
Number of subjects: 105
Study 36497620 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 105
Study 36497620 — intervention group
Group type: EXPERIMENTAL
Intervention: Body composition changes
Number of subjects: 105
Study 36497976 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoarticular cluster
Number of subjects: 740
Study 36497976 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor chronic disease cluster
Number of subjects: 740
Study 36497976 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychogeriatric cluster
Number of subjects: 740
Study 36497976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory cluster
Number of subjects: 740
Study 36498758 — intervention group
Group type: EXPERIMENTAL
Intervention: Fu's subcutaneous needling (FSN)
Number of subjects: 32
Study 36498758 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 32
Study 36498818 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IL-17C monoclonal antibody MOR106, administered for up to 12 weeks.
Number of subjects: 0
Study 36498818 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, but implied as standard treatment or placebo.
Number of subjects: 0
Study 36499023 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-induced hypoglycemia (2 mmol/L; 36 mg/dL)
Number of subjects: 46
Study 36499023 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hypoglycemia)
Number of subjects: 46
Study 36499525 — intervention group
Group type: EXPERIMENTAL
Intervention: IPAF group
Number of subjects: 40
Study 36499525 — intervention group
Group type: COMPARATOR
Intervention: CTD-ILD group
Number of subjects: 40
Study 36501072 — intervention group
Group type: EXPERIMENTAL
Intervention: 1−2 drinks/day (~12−24 g)
Number of subjects: 26
Study 36501177 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-Life exercise intervention
Number of subjects: 50
Study 36502794 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 95
Study 36502794 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) ibuprofen
Number of subjects: 95
Study 36503177 — intervention group
Group type: COMPARATOR
Intervention: RPM-conventional
Number of subjects: 1339
Study 36503177 — intervention group
Group type: COMPARATOR
Intervention: RPM-alert
Number of subjects: 1339
Study 36503252 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein(a) [Lp(a)] levels
Number of subjects: 377
Study 36503279 — intervention group
Group type: EXPERIMENTAL
Intervention: EMS-treated OHCAs
Number of subjects: 92913
Study 36503310 — intervention group
Group type: EXPERIMENTAL
Intervention: Milano-Torino staging (MiToS)
Number of subjects: 456
Study 36503310 — intervention group
Group type: EXPERIMENTAL
Intervention: King's staging
Number of subjects: 456
Study 36503413 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aerosolised Ad5-nCoV
Number of subjects: 419
Study 36503413 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aerosolised Ad5-nCoV
Number of subjects: 419
Study 36503413 — intervention group
Group type: COMPARATOR
Intervention: CoronaVac (control group)
Number of subjects: 419
Study 36503413 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 419
Study 36503429 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT alone
Number of subjects: 0
Study 36503429 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT with 1 month ADT
Number of subjects: 0
Study 36503429 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT with 6 months ADT and ARTA (enzalutamide 4×40 mg daily for 6 months)
Number of subjects: 0
Study 36503429 — intervention group
Group type: COMPARATOR
Intervention: MDT
Number of subjects: 0
Study 36503495 — intervention group
Group type: EXPERIMENTAL
Intervention: mtFIT
Number of subjects: 13131
Study 36503495 — intervention group
Group type: COMPARATOR
Intervention: FIT
Number of subjects: 13131
Study 36503500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support with positive end-expiratory pressure
Number of subjects: 0
Study 36503500 — intervention group
Group type: COMPARATOR
Intervention: T-piece
Number of subjects: 0
Study 36503505 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 157
Study 36503505 — intervention group
Group type: COMPARATOR
Intervention: Conventional Wound Treatment (CWT)
Number of subjects: 157
Study 36503505 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient NPWT
Number of subjects: 157
Study 36503505 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient CWT after NPWT
Number of subjects: 157
Study 36503610 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (PD-1 inhibitor) followed by SBRT (30 Gy in 3 to 5 fractions)
Number of subjects: 40
Study 36503690 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry-based identification and invitation for ultrasound examination of first-degree relatives to AAA patients.
Number of subjects: 1500
Study 36503690 — intervention group
Group type: COMPARATOR
Intervention: Control group without hereditary risk for AAA.
Number of subjects: 1500
Study 36503690 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of anxiety for disease and health-related quality of life (HRQoL).
Number of subjects: 1500
Study 36503690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of the study.
Number of subjects: 1500
Study 36503736 — intervention group
Group type: EXPERIMENTAL
Intervention: OCS-01 once daily
Number of subjects: 153
Study 36503736 — intervention group
Group type: EXPERIMENTAL
Intervention: OCS-01 BID
Number of subjects: 153
Study 36503736 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 153
Study 36503738 — intervention group
Group type: EXPERIMENTAL
Intervention: Napabucasin plus FOLFIRI
Number of subjects: 1253
Study 36503738 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI alone (control)
Number of subjects: 1253
Study 36504158 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg and 8 mg extended-release tablets
Number of subjects: 181
Study 36504158 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 2 mg and 4 mg extended-release beads-in-capsule (BIC)
Number of subjects: 181
Study 36504158 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg and 8 mg extended-release tablets and 4 mg BIC
Number of subjects: 181
Study 36504158 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin XL tablets
Number of subjects: 181
Study 36504254 — intervention group
Group type: EXPERIMENTAL
Intervention: CST-PM microbiome (polymicrobial)
Number of subjects: 688
Study 36504254 — intervention group
Group type: COMPARATOR
Intervention: CST-LC microbiome (Lactobacillus crispatus)
Number of subjects: 688
Study 36504254 — intervention group
Group type: EXPERIMENTAL
Intervention: CST-PM microbiome (polymicrobial) in women aged 20-24 years
Number of subjects: 688
Study 36504254 — intervention group
Group type: COMPARATOR
Intervention: CST-LI microbiome (Lactobacillus iners)
Number of subjects: 688
Study 36504254 — intervention group
Group type: COMPARATOR
Intervention: CST-GV microbiome (Gardnerella vaginalis)
Number of subjects: 688
Study 36504291 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad 24 mg extended release with allopurinol 300 mg
Number of subjects: 24
Study 36504291 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad 40 mg immediate release with allopurinol 300 mg
Number of subjects: 24
Study 36504291 — intervention group
Group type: COMPARATOR
Intervention: Matching placebos
Number of subjects: 24
Study 36504759 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological trauma assessment in FM patients
Number of subjects: 88
Study 36504759 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic events prior to the onset of pain
Number of subjects: 88
Study 36504759 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical symptoms assessment
Number of subjects: 88
Study 36504759 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain levels
Number of subjects: 88
Study 36505277 — intervention group
Group type: EXPERIMENTAL
Intervention: targeted high-throughput next-gen sequencing (tNGS)
Number of subjects: 20
Study 36505277 — intervention group
Group type: COMPARATOR
Intervention: traditional culture-based approach
Number of subjects: 20
Study 36505379 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 1576
Study 36505379 — intervention group
Group type: COMPARATOR
Intervention: No PVI
Number of subjects: 1576
Study 36505793 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib with pembrolizumab
Number of subjects: 9
Study 36505793 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (vemurafenib, cobimetinib, and pembrolizumab)
Number of subjects: 9
Study 36505793 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life assessments
Number of subjects: 9
Study 36505793 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse Events
Number of subjects: 9
Study 36505833 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 8-12mg once daily and sintilimab 200mg once every three weeks combined with radiotherapy (3Gy*10 fraction)
Number of subjects: 20
Study 36505833 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib and sintilimab combined with radiotherapy
Number of subjects: 20
Study 36505849 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Number of subjects: 128
Study 36505849 — intervention group
Group type: COMPARATOR
Intervention: Other TKIs
Number of subjects: 128
Study 36505885 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose luspatercept (0.6-1.25 mg/kg) for NTD patients
Number of subjects: 64
Study 36505885 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose luspatercept (0.6-1.25 mg/kg) for TD patients
Number of subjects: 64
Study 36505885 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose luspatercept (0.6-1.25 mg/kg)
Number of subjects: 64
Study 36506070 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerostin
Number of subjects: 39
Study 36506070 — intervention group
Group type: EXPERIMENTAL
Intervention: DKK-1
Number of subjects: 39
Study 36506070 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerostin and DKK-1 ratio
Number of subjects: 39
Study 36506077 — intervention group
Group type: EXPERIMENTAL
Intervention: FGM use with remote intervention
Number of subjects: 36
Study 36506077 — intervention group
Group type: COMPARATOR
Intervention: FGM use only (control group)
Number of subjects: 36
Study 36506445 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based educational information
Number of subjects: 325
Study 36506445 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 325
Study 36506562 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR7280, an oral gonadotropin-releasing hormone antagonist
Number of subjects: 0
Study 36506749 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg BID
Number of subjects: 0
Study 36506749 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 36506749 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg BID
Number of subjects: 0
Study 36506775 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg midazolam
Number of subjects: 312
Study 36506775 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg midazolam
Number of subjects: 312
Study 36506775 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 312
Study 36507576 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg subcutaneously every 4 weeks for 52 weeks
Number of subjects: 1059
Study 36507576 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 1059
Study 36507576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1059
Study 36507677 — intervention group
Group type: EXPERIMENTAL
Intervention: Telacebec (Q203) at doses of 20, 50, 100, 160, 250, and 320 mg, orally administered once daily for 14 days
Number of subjects: 47
Study 36507677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 36507686 — intervention group
Group type: EXPERIMENTAL
Intervention: Talquetamab (405 μg per kilogram weekly)
Number of subjects: 232
Study 36507686 — intervention group
Group type: EXPERIMENTAL
Intervention: Talquetamab (800 μg per kilogram every other week)
Number of subjects: 232
Study 36507690 — intervention group
Group type: EXPERIMENTAL
Intervention: Glofitamab monotherapy (12 cycles total) after pretreatment with obinutuzumab
Number of subjects: 155
Study 36507690 — intervention group
Group type: EXPERIMENTAL
Intervention: Glofitamab monotherapy
Number of subjects: 155
Study 36507736 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 2267
Study 36507738 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg psilocybin
Number of subjects: 79
Study 36507738 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg psilocybin
Number of subjects: 79
Study 36507738 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg psilocybin
Number of subjects: 79
Study 36507781 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated boost to the dominant intraprostatic nodule in stereotactic body radiation therapy, details on dosage and duration not available.
Number of subjects: 0
Study 36507973 — intervention group
Group type: EXPERIMENTAL
Intervention: lonafarnib
Number of subjects: 2
Study 36507973 — intervention group
Group type: COMPARATOR
Intervention: untreated cohort
Number of subjects: 2
Study 36508217 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisectoral agriculture and livelihood intervention (loan for irrigation pump, fertilizer, seeds, pesticides, training in sustainable agriculture and financial literacy)
Number of subjects: 720